Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of
denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal …

A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has
been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ) …

Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases
in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive …

Background. The aim of this study was to compare retrospectively the effect of three different
treatment protocols on the healing outcome in patients with established medication-related …

Objective The most debated topic about medication-related osteonecrosis of the jaws
(MRONJ) is its therapy, as there are no definitive guidelines. The aims of this systematic …

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of
antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating …

Objectives To establish osteonecrosis of the jaws in rats treated with different doses of
zoledronic acid (ZA). Methods Male Wistar rats (n= 6–7) received three consecutive weekly …

Medication-related osteonecrosis of the jaw (MRONJ) is a relatively new pathology that
involves the head and neck region. The first cases were described by Marx in 2003 (Marx …

Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer.
They improve quality of survival by reducing skeletal-related events, treating …

Purpose To identify the risk factors associated with relapse or treatment failure after surgery
for bisphosphonate-related osteonecrosis of the jaw (BRONJ) in patients with osteoporosis …